P3-011: Phenotypic differences between sexes and absence of human papillomavirus and Epstein-Barr virus in non-smokers with lung adenocarcinoma in Singapore  by Lim, Wan-Teck et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S503
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
0-3. For ER, PR and EGFR, 0 was scored as ‘negative’; for HER2, 0-1 
was scored as ‘negative’.
Statistical Analyses: Wilcoxon-signed rank (WSR) test was used to 
assess differences between matched samples. Fisher’s exact test and χ2 
analysis were used to assess the correlations between various parameters.
Results:
Table 1: Comparing ERα, ERβ, PR, HER2 protein levels between tumors and 
matched normals. Analysis is by WSR test.
Protein n Expression in Tumor p value
ERa 26 Higher <0.001
ERb 22 No diﬀerence 0.739
PR 26 No diﬀerence 0.739
HER2 27 Higher 0.005
Table 2: Correlation of female gender with various parameters: histological 
subtype and diﬀerentiation, ERα, ERβ, PR, EGFR, HER2 status. Analysis is by 
χ2 test; * = Fisher’s exact test.
Parameter n Female p value
Adenocarcinoma 33 14 (42%)  
Squamous Cell Carcinoma 16 1 (6%) 0.018*
Well Diﬀerentiated 6 4 (67%)  
Moderately Diﬀerentiated 27 6 (22%)  
Poorly Diﬀerentiated 16 5 (31%) 0.102
ERa negative 17 6 (35%)  
ERa positive 32 9 (28%) 0.747*
ERb negative 18 8 (44%)  
ERb positive 30 6 (20%) 0.103*
PR negative 6 2 (33%)  
PR positive 43 13 (30%) >0.999*
HER2 negative 40 10 (25%)  
HER2 positive 9 5 (56%) 0.110*
EGFR negative 31 7 (23%)  
EGFR positive 18 8 (44%) 0.124*
Conclusions: In this series of 49 tumors, there appears to be overex-
pression of ERα and HER2 in NSCLC, compared with matched normal 
tissues. Female NSCLC seems to be more frequently associated with 
adenocarcinoma subtype, with a trend towards well-differentiated 
tumors, ERβ downregulation, EGFR and HER2 overexpression. Addi-
tional work is required to further verify and expand upon these results.
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Background: To determine any phenotype differences between males 
and females with non-smoking lung adenocarcinoma and the presence 
of human papillomavirus (HPV) and Epstein-Barr virus (EBV) in such 
a population.
Materials and Methods: Patients with non-smoking adenocarcinoma 
of the lung were analysed from a case series database of patients 
from 1999 to 2002 in the National Cancer Centre Singapore. Associa-
tion between categorical factors and gender was analysed by Pearson 
chi-squared of Fisher’s exact test. Kaplan-Meier method was used to 
estimate the survival function and log-rank statistic test was used to test 
for survival difference between male and female within each level of 
factor. A P-value of less than 0.05 was considered statistically signiﬁcant 
for all statistical tests. All analyses were performed using SPSS 11.5 for 
Windows. Presence of human papillomavirus and Epstein-Barr Virus 
was tested using the Ventana Benchmark INFORM system (Ventana 
Medical Systems, Tucson, Az, USA) consisting of probes: HPV Family 
16 (HPV genotypes 16, 18, 31, 33, 35, 39, 51, 52, 56, 58, and 66) and 
HPV 6 (HPV genotypes 6 and 11) and EBER (Epstein-Barr early RNA). 
Results: Two hundred patients were analyzed. The ratio of females to 
males was 2.8:1. Patient demographics were compared between sexes 
and there were no signiﬁcant differences between males and females in 
terms of comorbidities, performance status at presentation, or stage of 
presentation at diagnosis. About two-thirds of patients were metastatic 
at diagnosis in both sexes. Both sexes had also similar sites of distant 
metastases at presentation. The survival functions between males and 
females were not signiﬁcantly different from each other within each 
level of a factor except for those who had best supportive care (support-
ive / no treatment) or surgery. It appeared that females tend to survive 
longer than male when they were on best supportive care (P = 0.026). 
Also females seemed to have longer median survival time (69 months) 
compare to males (38 months) if they had surgery. However, the dif-
ference is quite weak, with a P-value of 0.059. Out of the two hundred 
patients for clinical analysis, only 44 (22%) tissue specimens of suf-
ﬁcient quality were suitable for in-situ hybridization methods. Of these 
9 (20%) were males and 35 (80%) from females. There was absence 
of HPV and EBV by in-situ hybridization in all the tumor specimens 
examined. 
Conclusions: There are no signiﬁcant differences in the clinical course 
and phenotypic characteristics of non-smoking adenocarcinoma of 
the lung between sexes. It is likely that non-smoking adenocarcinoma 
constitute a biologically independent subset of NSCLC that does not 
depend on sex. The absence of EBV and HPV in the tumor specimens 
examined here suggest that in certain populations, there is a low likeli-
hood that these viruses are likely to be causative for lung cancer.
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